We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Neurocrine Biosciences Inc (NBIX) Com Stk NPV (CDI)

Sell:$108.83 Buy:$149.79 Change: $0.46 (0.34%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$108.83
Buy:$149.79
Change: $0.46 (0.34%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$108.83
Buy:$149.79
Change: $0.46 (0.34%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Contact details

Address:
6027 EDGEWOOD BEND COURT
SAN DIEGO
92130
United States
Telephone:
+1 (858) 6177600
Website:
https://www.neurocrine.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NBIX
ISIN:
US64125C1099
Market cap:
$13.71 billion
Shares in issue:
101.25 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kyle Gano
    President, Chief Executive Officer, Director
  • Matthew Abernethy
    Chief Financial Officer
  • Julie Cooke
    Chief Human Resource Officer
  • Jude Onyia
    Chief Scientific Officer
  • Eric Benevich
    Chief Commercial Officer
  • David Boyer
    Chief Corporate Affairs Officer
  • Ingrid Delaet
    Chief Regulatory Officer
  • Eiry Roberts
    Chief Medical Officer
  • Darin Lippoldt
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.